Prescient Therapeutics Ltd (ASX: PTX) Share Price and News

Dr Campbell has more than 25 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple Australian and international biotechnology companies. In 2011 ChemGenex was sold to Cephalon for $230M. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. He is a Member of the Risk Committee.

Ms Farris is an experienced non-executive director, governance, risk and communications professional in the listed, public and not-for-profit sectors, possessing a track record in the planning, delivery and oversight of strategic corporate, funding, governance and risk projects across industries including life sciences, investment, agriculture, not-for-profit and music industry marketing. She is Chair of the Risk Committee.

Dr Ebens during that time Dr Ebens as head of Research at Vera Therapeutics, a San Francisco, California based, clinical stage biotechnology company. Dr Ebens is a drug developer, having overseen the advancement of a dozen drug development projects from concept to clinical development including polatuzumab and mosunetuzumab which are FDA approved and marketed for use in B-cell malignacies. At Juno, Dr Ebens was instrumental in establishing the scientific capabilities of the company in the emerging field of CAR-T. Previously, Dr Ebens held senior executive positions at global pharma and biotechnology leaders Genentech and Exelixis, where he worked from concept to clinic across multiple therapeutic platforms including targeted small-molecule therapies, antibodies, antibody-drug conjugates, and T cell recruiting antibodies. He has also held roles in biotech companies including Bioseek and NGM Biopharmaceuticals. He is a Member of the Risk Committee.

Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute.

Dr Shepherd is a medical professional with 25 years of experience in medicine and a track record in driving success in various specialist consulting businesses. Dr Shepherd combines his medical expertise with business acumen as well as through his investment in disruptive healthcare technologies. He actively contributes to the healthcare industry through his involvement with the Medical Device Partnering Program at Flinders University and his lecturing for the Royal Australian College of General Practitioners registrar training program in South Australia. He is a Member of the Risk Committee.

-

-

-

-